Electroacupuncture plus on‐demand gastrocaine for refractory functional dyspepsia: Pragmatic randomized trial

• Published in: Journal of gastroenterology and hepatology Vol. 34; no. 12; pp. 2077 - 2085
• Main Authors: Chung, Vincent CH, Wong, Charlene HL, Wu, Irene XY, Ching, Jessica YL, Cheung, William KW, Yip, Benjamin HK, Chan, Kam Leung, Cheong, Pui Kuan, Wu, Justin CY
• Format: Journal Article
• Language: English
• Published: Australia 01.12.2019
• Subjects: acupuncture; functional dyspepsia; on‐demand antacid; randomized trial; acupuncture; on-demand antacid; functional dyspepsia; randomized trial
• ISSN: 0815-9319; 1440-1746
• DOI: 10.1111/jgh.14737

Background and Aim Treatment options for functional dyspepsia (FD) refractory to pharmacological treatments are limited but the effectiveness of electroacupuncture (EA) is uncertain. We assessed the effectiveness of EA combined with on‐demand gastrocaine. Methods We conducted a single‐center, assessor‐blind, randomized parallel‐group 2‐arm trial on Helicobacter pylori negative FD patients of the postprandial distress syndrome subtype refractory to proton pump inhibitor, prokinetics, or H2 antagonists. Enrolled participants were block randomized in a 1:1 ratio, with concealed random sequence. The treatment and control groups both received on‐demand gastrocaine for 12 weeks, but only those in treatment group were offered 20 sessions of EA over 10 weeks. The primary endpoint was the between‐group difference in proportion of patients achieving adequate relief of symptoms at week 12. Results Of 132 participants randomly assigned to EA plus on‐demand gastrocaine (n = 66) or on‐demand gastrocaine alone (n = 66), 125 (94.7%) completed all follow‐up at 12 weeks. The EA group had a compliance rate 97.7%. They had a significantly higher likelihood in achieving adequate symptom relief at 12 weeks, with a clinically relevant number needed to treat (NNT) value of 2.36 (95% CI: 1.74, 3.64). Among secondary outcomes, statistically and clinically significant improvements were observed among global symptom (NNT = 3.85 [95% CI: 2.63, 7.69]); postprandial fullness and early satiation (NNT = 5.00 [95% CI: 2.86, 25.00]); as well as epigastric pain, epigastric burning, and postprandial nausea (NNT = 4.17 [95% CI: 2.56, 11.11]). Adverse events were minimal and nonsignificant. Conclusion For refractory FD, EA provides significant, clinically relevant symptom relief when added to on‐demand gastrocaine (ChiCTR‐IPC‐15007109).